Immix Biopharma
Immix Biopharma is a clinical-stage biopharmaceutical company developing NXC-201, a BCMA-targeted CAR-T cell therapy produced via its proprietary N-GENIUS platform, targeting relapsed/refractory AL amyloidosis patients — a rare disease with no FDA-approved treatments — and other plasma cell-driven immune-mediated diseases.
- Company typePublic
- Founded2022
- HeadquartersLos Angeles, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Immix Biopharma does
Immix Biopharma, Inc. (Nasdaq: IMMX) is a clinical-stage biopharmaceutical company headquartered in Los Angeles, California and incorporated in Delaware, founded in 2022 by Ilya Rachman, MD PhD to develop cell therapies for relapsed/refractory AL amyloidosis and other serious diseases. The company's lead candidate NXC-201 (formerly HBI0101) is a sterically-optimized, BCMA-targeted autologous CAR-T cell therapy produced through the proprietary N-GENIUS platform with EXPAND technology, into which global IP rights were licensed from Hadassah Israel. NXC-201 incorporates three proprietary modifications — Optimized CD3ζγ signaling, Enhanced CD8 Hinge acting as a "digital filter," and COBRA binder technology — designed to deliver precise intracellular signaling while reducing non-specific activation and cytokine release.
In May 2026 the company reported a 95% complete response rate (19 of 20 patients) in its U.S. NEXICART-2 Phase 1b/2 registrational trial, with 0% neurotoxicity across all treated patients and a median CRS duration of 1 day (4-8x shorter than competing BCMA CAR-Ts). The company holds four stacked regulatory designations for NXC-201 — FDA Breakthrough Therapy Designation (January 2026), FDA RMAT, FDA Orphan Drug Designation, and EU EMA Orphan Drug Designation — and is the only granted FDA Breakthrough Designation for an active development-stage therapy in relapsed/refractory AL amyloidosis. NEXICART-2 enrollment of 40 patients was completed March 30, 2026, with topline Phase 2 results expected Q3 2026, followed by BLA submission and a planned U.S. commercial launch in 2028.
The company is pre-revenue and funds development through public equity offerings, having raised approximately $265 million in gross proceeds across February 2024 ($15M), December 2025 ($100M upsized), and May 2026 ($150M) underwritten offerings, with an additional $100M ATM facility, providing an operational runway into mid-2028. Upon BLA approval, NXC-201 is expected to be commercialized as a one-time CAR-T cell therapy administered through specialty hematology/oncology and academic medical centers, priced analogously to approved CAR-Ts (Breyanzi, Carvykti, Abecma). Commercial readiness is being built through the additions of Chief Medical Officer Richard Graydon (former Merck/J&J, BLA experience on KEYTRUDA, DARZALEX, CARVYKTI, IMBRUVICA) and Chief Commercial Officer Michael Grabow (former Chimerix, Spectrum, Amgen, 10+ drug launches). The AL amyloidosis market alone represents $1.4-2.8B in annual sales potential, with a broader $10B+ TAM across plasma cell-driven immune-mediated diseases in neurology, rheumatology, hematology, and vascular indications.
Immix Biopharma firmographics
Firmographics- Name
- Immix Biopharma
- Legal name
- Immix Biopharma, Inc.
- Website
- https://immixbio.com
- Company type
- Public
- Founded year
- 2022
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Immix Biopharma is a clinical-stage biopharmaceutical company developing NXC-201, a BCMA-targeted CAR-T cell therapy produced via its proprietary N-GENIUS platform, targeting relapsed/refractory AL amyloidosis patients — a rare disease with no FDA-approved treatments — and other plasma cell-driven immune-mediated diseases.
- Ownership category
- akta.pro rank
Immix Biopharma industry classification
Industry- Product category
- CAR-T Cell Therapy
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (3254)
- SIC
- Pharmaceutical Preparations (2834), In Vitro & In Vivo Diagnostic Substances (2835)
- akta.pro primary industry
- CAR-T & TCR-T Therapies (HLAAABAC)
- akta.pro secondary industry
- Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods) (HLAAABAL)
Keywords
Where Immix Biopharma is headquartered
LocationHeadquarters
- HQ city
- Los Angeles
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Immix Biopharma business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Others
Revenue model
- Future Biopharmaceutical Product Sales (Pre-Revenue): Immix Biopharma is a clinical-stage biopharmaceutical company that is not yet generating product revenue. Upon BLA approval, NXC-201 is expected to be commercialized as a one-time CAR-T cell therapy for relapsed/refractory AL Amyloidosis (and later expanded indications). As a one-time cell therapy, the model is closer to a one-time treatment per patient (analogous to other approved CAR-Ts such as Breyanzi, Carvykti, Abecma).
- Capital Markets Financing (Equity Offerings): To date, the company has funded development through equity financings including a $15M public offering in February 2024, an upsized $100M underwritten offering in December 2025 (net proceeds ~$93.7M), and a $150M underwritten offering in May 2026 (net proceeds ~$140.65M). Also amended an at-the-market offering agreement for up to $100M with Citizens JMP Securities. These are not product revenue but are the company's primary cash inflows pre-commercialization.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | — | No commercial product pricing available; pre-commercial clinical-stage biotech |
Go-to-market motion4 records
Distribution channels3 records
Marketing channels8 records
Immix Biopharma product offering
Product offeringCore offering
Immix Biopharma develops NXC-201, a BCMA-targeted, sterically-optimized autologous CAR-T cell therapy, for the treatment of relapsed/refractory AL amyloidosis and other plasma cell-driven immune-mediated diseases. The company leverages its proprietary N-GENIUS cell therapy platform with EXPAND technology, incorporating three modifications (Optimized CD3ζγ signaling, Enhanced CD8 Hinge 'digital filter', and COBRA binder) to deliver 'digital' signaling precision while minimizing toxicity. Development is conducted through the ex-U.S. NEXICART-1 study and U.S. Phase 1b/2 NEXICART-2 registrational trial, with FDA Breakthrough Therapy, RMAT, and Orphan Drug designations in place.
Product overview
Immix Biopharma offers a platform-plus-candidate architecture rather than a single unified product: the proprietary N-GENIUS Platform with EXPAND technology is the discovery and manufacturing engine used to generate sterically-optimized CAR-T cell therapies, and NXC-201 is the lead BCMA-targeted CAR-T candidate produced from that platform. The clinical development of NXC-201 is conducted through two named programs — the ex-U.S. NEXICART-1 study and the U.S. Phase 1b/2 NEXICART-2 trial — which together support the lead indication of relapsed/refractory AL amyloidosis and have underpinned FDA Breakthrough Therapy, RMAT, and Orphan Drug designations as well as EU EMA Orphan Drug Designation.
Differentiator
Problem solved
Functional benefit
Brands
- NXC-201: Lead product candidate: a sterically-optimized BCMA-targeted chimeric antigen receptor T (CAR-T) cell therapy for relapsed/refractory AL Amyloidosis and immune-mediated diseases.
- N-GENIUS
- Be Proactive in AL
Products and services
- NXC-201
Quantifiable outcome
- 95% complete response rate (19 of 20 patients) in NEXICART-2 interim update for relapsed/refractory AL Amyloidosis, with all CRs reached within 1 year of follow-up and no relapses observed to date
- +5 more outcomes
Companies that use Immix Biopharma
Customer profileSegments3 records
Ideal customer profiles2 records
Immix Biopharma technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature8 records
Immix Biopharma partnerships and signals
Strategic signalPartnerships
Twelve partnerships are on record, tiered flagship (lead site for u.s. nexicart-2 trial; lead investigator heather landau, md), flagship (origin of nxc-201 / hbi0101 ip), major (nexicart-2 trial site; kol engagement), major (training/clinical research; trial site), major (nexicart-2 trial site), core (legal counsel), core (auditor), core (transfer agent), advisory (scientific advisor) and advisory (scientific advisor; kol).
- Memorial Sloan Kettering Cancer Center (MSKCC)flagship (lead site for u.s. nexicart-2 trial; lead investigator heather landau, md)Memorial Sloan Kettering Cancer Center is the lead site for the U.S. NEXICART-2 registrational Phase 2 clinical trial of NXC-201 for relapsed/refractory AL Amyloidosis. Heather Landau, MD, Director of the Amyloidosis Program at MSKCC, serves as lead investigator and Scientific Advisor to Immix Biopharma. She has authored more than 100 peer-reviewed publications and presented NEXICART-2 data at ASH 2025, ASCO 2025, and ASTCT 2026.
- Hadassah Israel (Hadassah Medical Center)flagship (origin of nxc-201 / hbi0101 ip)Hadassah Israel is the originator of the NXC-201 (formerly HBI0101) academic BCMA-CAR-T program. In 2022, Immix Biopharma licensed-in global rights to the intellectual property from Hadassah Israel following a systematic search to identify breakthrough cell therapies. The Hadassah team (Eyal Lebel, Nathalie Asherie, Cyrille Cohen, Polina Stepensky, Moshe Gatt) has been a continuous clinical research partner, with multiple publications in Journal of Clinical Oncology, Haematologica, and Clinical Cancer Research.
- Cleveland Clinicmajor (nexicart-2 trial site; kol engagement)Cleveland Clinic is one of the NEXICART-2 clinical trial sites. Shahzad Raza, MD of Cleveland Clinic serves as a co-investigator and KOL, participating in KOL events to discuss NEXICART-2 Phase 2 results. Logo displayed on company 'Industry Leading Partners' page.
- Stanford Medicine (Stanford University)major (nexicart-2 trial site; kol engagement)Stanford Medicine is one of the NEXICART-2 clinical trial sites. Michaela Liedtke, MD, Stanford Amyloid Center Co-Director, serves as a KOL and Scientific Advisor. Logo displayed on company 'Industry Leading Partners' page.
- Harvard (Harvard Medical School / Massachusetts General Hospital)major (training/clinical research; trial site)Harvard's Massachusetts General Hospital is referenced as the training site for Chief Medical Officer Richard Graydon, MD PhD. Harvard logo is displayed on the company 'Industry Leading Partners' page as an institutional partner.
- UC San Diegomajor (nexicart-2 trial site)UC San Diego is one of the NEXICART-2 clinical trial sites for the NXC-201 CAR-T cell therapy. Logo displayed on the company 'Industry Leading Partners' page.
- Sheppard, Mullin, Richter & Hampton LLPcore (legal counsel)Sheppard, Mullin, Richter & Hampton LLP (30 Rockefeller Plaza, New York, NY 10112) serves as Immix Biopharma's legal counsel, per the Investor FAQ on the company website.
- Crow LLPcore (auditor)Crow LLP serves as Immix Biopharma's auditor, per the Investor FAQ on the company website.
- Philadelphia Stock Transfer (PST)core (transfer agent)Philadelphia Stock Transfer, Inc. (2320 Haverford Road, Suite 230, Ardmore, PA 19003) serves as Immix Biopharma's transfer agent.
- Tufts University School of Medicine (Dr. Raymond Comenzo)advisory (scientific advisor)Dr. Raymond Comenzo, Director of the Myeloma and Amyloid Program and Director of the Cell Therapy Laboratory at Tufts Medical Center, and Professor of Medicine at Tufts University School of Medicine, serves as a Scientific Advisor to Immix Biopharma. Board certified in Internal Medicine and Hematology.
- Boston University (Dr. Vaishali Sanchorawala)advisory (scientific advisor; kol)Dr. Vaishali Sanchorawala, Skinner Professor of Amyloidosis Research at Boston University Chobanian & Avedisian School of Medicine and Director of the Amyloidosis Center at Boston Medical Center, serves as a Scientific Advisor to Immix Biopharma and KOL speaker. Quoted on the company website.
- Columbia University (Dr. Suzanne Lentzsch)advisory (scientific advisor)Dr. Suzanne Lentzsch, Professor of Clinical Medicine and Director of the Multiple Myeloma and Amyloidosis Program at the College of Physicians and Surgeons of Columbia University and New York Presbyterian Hospital, serves as a Scientific Advisor to Immix Biopharma. Co-founder of Caelum Biosciences (acquired by AstraZeneca).
Scale indicators13 records
Recent moves6 records
Expansion highlights6 records
Immix Biopharma competitors and assessment
Company assessmentBroad incumbents
- Bristol Myers Squibb: BMS markets Abecma, the first FDA-approved BCMA-directed CAR-T cell therapy for multiple myeloma, making it the most direct large-cap competitor in the BCMA CAR-T space. Both companies compete in BCMA-targeted autologous CAR-T development with overlapping manufacturing and clinical infrastructure.
- Johnson & Johnson (Janssen) / Legend Biotech: J&J co-developed with Legend Biotech Carvykti, the leading FDA-approved BCMA CAR-T for multiple myeloma with industry-leading efficacy benchmarks. Directly comparable as a BCMA CAR-T competitor with established commercial CAR-T infrastructure that could expand into AL amyloidosis.
- AstraZeneca (Alexion): AstraZeneca's Alexion rare-disease franchise acquired Caelum Biosciences (co-founded by Immix SAB member Suzanne Lentzsch) and has been active in AL amyloidosis. Comparable as a large-cap incumbent with rare-hematology commercial reach that could be a partner or competitor in the AL amyloidosis space.
Direct peers
- Allogene Therapeutics: Allogene is a clinical-stage CAR-T company developing both allogeneic (off-the-shelf) and autologous CAR-T candidates, including BCMA-directed programs. Comparable as a public clinical-stage CAR-T peer pursuing similar hematology indications, with a complementary allogeneic approach.
- CRISPR Therapeutics: CRISPR Therapeutics develops gene-edited cell therapies including allogeneic CAR-T candidates (e.g., CTX112 targeting CD19 and BCMA). Comparable as a clinical-stage public CAR-T peer with a similar regulatory pathway and platform-based cell therapy strategy.
- Caribou Biosciences: Caribou Biosciences develops allogeneic CAR-T cell therapies using CRISPR-based genome editing, with clinical programs in hematologic malignancies. Comparable as a clinical-stage CAR-T peer with similar modality, regulatory pathway, and platform expansion thesis.
- 2seventy bio: 2seventy bio co-developed Abecma with BMS and remains the dedicated cell therapy entity post-spin-off. Comparable as a focused, clinical-to-commercial stage CAR-T peer with deep BCMA CAR-T expertise and ongoing multiple myeloma development.
Emerging players
- Precision BioSciences: Precision BioSciences develops in vivo gene-edited cell therapies including CAR-T candidates for hematologic malignancies. Comparable as an early-to-mid-stage cell therapy peer with adjacent modality and overlapping target indications.
- Prothena Corporation: Prothena is a clinical-stage biotech developing therapies for amyloid-related diseases including AL amyloidosis. Directly comparable as a small-cap public biotech tackling the same orphan indication with a complementary protein-targeting approach.
- Adaptimmune Therapeutics: Adaptimmune develops engineered T-cell therapies including SPEAR T-cells for hematologic malignancies, recently gaining FDA approval for Tecelra. Comparable as a clinical-to-commercial stage cell therapy peer with similar regulatory trajectory and platform-based expansion thesis.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Immix Biopharma social profiles
Digital presenceImmix Biopharma compliance and trust
Trust signalCompliance4 records
Immix Biopharma financial estimates
Financial estimateRevenue estimate
Valuation estimate
Immix Biopharma leadership team
Management profileNumber of profiles
Profiles8 records
Immix Biopharma funding detail
Funding detailFunding overview
Funding rounds5 records
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Immix Biopharma M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Immix Biopharma
What does Immix Biopharma do?
Immix Biopharma develops NXC-201, a BCMA-targeted, sterically-optimized autologous CAR-T cell therapy, for the treatment of relapsed/refractory AL amyloidosis and other plasma cell-driven immune-mediated diseases. The company leverages its proprietary N-GENIUS cell therapy platform with EXPAND technology, incorporating three modifications (Optimized CD3ζγ signaling, Enhanced CD8 Hinge 'digital filter', and COBRA binder) to deliver 'digital' signaling precision while minimizing toxicity. Development is conducted through the ex-U.S. NEXICART-1 study and U.S. Phase 1b/2 NEXICART-2 registrational trial, with FDA Breakthrough Therapy, RMAT, and Orphan Drug designations in place.
Is Immix Biopharma a public or private company?
Immix Biopharma is a public company. It is classified as public and is currently operating.
When was Immix Biopharma founded?
Immix Biopharma was founded in 2022. It employs 11 to 50 people.
Where is Immix Biopharma based?
Immix Biopharma is headquartered in Los Angeles, United States, in the North America region.
How does Immix Biopharma make money?
Two revenue lines are on record. Future Biopharmaceutical Product Sales (Pre-Revenue) is the primary driver. The others are capital Markets Financing (Equity Offerings).
Who are Immix Biopharma's main competitors?
Broad incumbents on record are Bristol Myers Squibb, Johnson & Johnson (Janssen) / Legend Biotech and AstraZeneca (Alexion). Direct peers are Allogene Therapeutics, CRISPR Therapeutics, Caribou Biosciences and 2seventy bio. Emerging players are Precision BioSciences, Prothena Corporation and Adaptimmune Therapeutics.
Does Immix Biopharma have an API?
No public API is recorded for Immix Biopharma.
What industry is Immix Biopharma in?
Immix Biopharma's product category is CAR-T Cell Therapy. Its primary akta.pro industry code is HLAAABAC, CAR-T & TCR-T Therapies, with a secondary code of HLAAABAL, Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods). Its NAICS code is 325414 and its SIC code is 2834.